Allergic Rhinitis Treatment Market 2021-2027 Trends, Research Report, Growth Trends, Opportunities, Forecast to 2027


Allergic rhinitis or hay fever is an IgE-mediated disorder caused by allergens such as mold or tress, animal, dander, house dust mites, weed pollens, and grass. It can occur in two different forms namely, seasonal and perennial, which causes mild or moderate to severe inflammation within the nose. Some of the major apparent symptoms of allergic rhinitis include nasal congestion, rhinorrhea, sneezing, nasal itching, and itchy eyes, or it could be related to asthma as well. Allergic rhinitis and sinusitis are linked to each other, as allergic rhinitis blocks the nose, which blocks the sinuses. In 2015, based on World Allergy Organization, over 400 million people suffered from allergic rhinitis worldwide. Moreover, in the U.S., 10-30% adults and around 40% children were afflicted with allergic rhinitis.

 

The global Allergic Rhinitis Treatment Market is estimated to account fully for US$ 13,950.7 Mn with regards to value and is expected to achieve US$ 17,863.6 Mn by the finish of 2027.

 

Lack of cure is likely to hinder growth of the global Allergic Rhinitis Treatment Market. There is no remedy for allergic rhinitis. However, the results of the problem could be lessened with the usage of nasal sprays and antihistamine medications. High incidence of asthma is expected to supply lucrative growth opportunities for players in the global allergic rhinitis treatment market. For instance, based on The Global Asthma Report 2018, around 300 million people have asthma worldwide, and the quantity is expected to achieve 100 million by 2025.

 

Manufacturers are developing a variety of drugs and nasal sprays for treating allergic rhinitis. This in turn, is likely to fuel growth of the allergic rhinitis drugs market in the near future. For instance, in March 2017, the U.S. Food and Drug Administration (FDA) approved Odactra drug, manufactured by Catalent Pharma Solutions Limited, the first allergen extract to be administered beneath the tongue (sublingually), to deal with house dust mite (HDM)-induced nasal inflammation (allergic rhinitis), with or without eye inflammation (conjunctivitis), for individuals aged between18 and 65 years.

Comments

Popular posts from this blog

With the use of High-Frequency alternating current, Radiofrequency Ablation Device convert Electromagnetic Energy into Heat Energy

The Isocyanates Market to Witness Robust Growth in North America and Asia Pacific

Air Purifier works as a Sanitizer in the air which helps in reducing pollutants, allergens, and toxins